Skip to content

Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa

Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05141838
Enrollment
110
Registered
2021-12-02
Start date
2020-11-21
Completion date
2023-01-31
Last updated
2021-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullosa Epidermolysis, Osteopenia, Osteoporosis, Phosphorus and Calcium Disorders, Vitamin D Deficiency

Keywords

Children, Only

Brief summary

This retrospective prospective study is aimed at studying the level of vitamin D supply and identifying markers of bone tissue remodeling in order to develop approaches to the prevention of osteopenia and osteoporosis in children with congenital epidermolysis bullosa.

Detailed description

This retrospective prospective interventional study will examine vitamin D availability and its relationship with clinical disease, patient gender and age, and season. The mechanisms of impairment of phosphorus-calcium metabolism and bone tissue metabolism will be analyzed on the basis of biochemical parameters and instrumental research methods in children with dystrophic epidermolysis bullosa in order to develop personalized approaches for correcting vitamin D status and bone metabolism disorders in children with epidermolysis bullosa, followed by an assessment of their clinical efficacy.

Interventions

DRUGVitamin D

Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state

DIETARY_SUPPLEMENTOral nutritional supplement

Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition

Sponsors

National Medical Research Center for Children's Health, Russian Federation
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Verified diagnosis of epidermolysis bullosa; * Signing by parents (legal representatives) of informed consent to participate in the study and fulfill the requirements of the study

Exclusion criteria

* not planned

Design outcomes

Primary

MeasureTime frameDescription
Vitamin D levelBaselineStudy of the provision of vitamin D in children with dystrophic and simple forms of epidermolysis bullosa based on the level of 25 (OH) vitamin D (25 hydroxycholecalciferol) in the blood
Phosphorus-calcium metabolism assessmentBaselineStudy of levels of calcium, phosphorus, parathyroid hormone, creatinine, magnesium, albumin in the blood
Assessment of the state of bone tissueBaselineStudy of levels of alkaline phosphatase, osteocalcin, b-CrossLaps, P1NP in the blood
Assessment of indicators of physical developmentBaselineZ-score calculation (weight-for-height z-score)

Secondary

MeasureTime frameDescription
Assessment of bone mineral densityBaselinedual-energy X-ray densitometry
Bone age assessmentBaselineX-ray of the bones of the hand with an assessment of bone age

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026